Search
Check Out Our Sponsors
Latest topics
Cutaneous side effects of EGFR inhibitors - appearance and management.
Page 1 of 1
Cutaneous side effects of EGFR inhibitors - appearance and management.
Dtsch Med Wochenschr. 2010 Jan;135(4):149-154.
Cutaneous side effects of EGFR inhibitors - appearance and management.
Wollenberg A, Kroth J, Hauschild A, Dirschka T.
Klinik und Poliklinik für Dermatologie und Allergologie, Ludwig-Maximilians Universität München.
Epidermal growth factor receptor (EGFR) inhibitors such as cetuximab, erlotinib, panitumumab und gefitinib, are increasingly used for the treatment of advanced, metastatic, or recurrent tumours like colorectal carcinoma, non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN) and pancreatic cancer. For this reason the treatment of common cutaneous side effects of EGFR inhibitors has become important: they stigmatize the patient in daily life and may lead to efficacious therapie being discontinued. Depending on the particular EGFR inhibitor, an acneiform rash occurs in 30 to 90 % of patients. Severity, site, stage of eruptions and individual response influence the decision of treatment in the given case. It follows the forms of treatment for acne and rosacea, including topical and systemic antibiotics for their antimicrobial effect and anti-inflammatory effect, sometimes in combination with topical steroids. After several weeks additional sebostatic skin reactions, paronychia and changes in the hair structure may occur, calling for individualized treatment. Only multidisciplinary collaboration between oncologists, radiotherapist and dermatologists may provide an optimal patient care. This article gives an overview of the occurrence and latest treatment options of the cutaneous side effects caused by treatment with EGFR inhibitors. Georg Thieme Verlag KG Stuttgart · New York.
Cutaneous side effects of EGFR inhibitors - appearance and management.
Wollenberg A, Kroth J, Hauschild A, Dirschka T.
Klinik und Poliklinik für Dermatologie und Allergologie, Ludwig-Maximilians Universität München.
Epidermal growth factor receptor (EGFR) inhibitors such as cetuximab, erlotinib, panitumumab und gefitinib, are increasingly used for the treatment of advanced, metastatic, or recurrent tumours like colorectal carcinoma, non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN) and pancreatic cancer. For this reason the treatment of common cutaneous side effects of EGFR inhibitors has become important: they stigmatize the patient in daily life and may lead to efficacious therapie being discontinued. Depending on the particular EGFR inhibitor, an acneiform rash occurs in 30 to 90 % of patients. Severity, site, stage of eruptions and individual response influence the decision of treatment in the given case. It follows the forms of treatment for acne and rosacea, including topical and systemic antibiotics for their antimicrobial effect and anti-inflammatory effect, sometimes in combination with topical steroids. After several weeks additional sebostatic skin reactions, paronychia and changes in the hair structure may occur, calling for individualized treatment. Only multidisciplinary collaboration between oncologists, radiotherapist and dermatologists may provide an optimal patient care. This article gives an overview of the occurrence and latest treatment options of the cutaneous side effects caused by treatment with EGFR inhibitors. Georg Thieme Verlag KG Stuttgart · New York.
_________________
My regimen
http://www.immortalhair.org/mpb-regimen
Now available for consultation (hair and/or health)
http://www.immortalhair.org/health-consultation
Similar topics
» Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management.
» Depression could be a long-term side effect of 5-alpha reductase inhibitors (Anti-DHT drugs). General risk is increased by 23%, odds by roughly 19% - The older the subjects the more likely side effects would occur…
» Epidermal EGFR Controls Cutaneous Host Defense and Prevents Inflammation.
» Cutaneous Adverse Effects Associated With the Tyrosine-Kinase Inhibitor Cabozantinib.
» Va&&ine side effects
» Depression could be a long-term side effect of 5-alpha reductase inhibitors (Anti-DHT drugs). General risk is increased by 23%, odds by roughly 19% - The older the subjects the more likely side effects would occur…
» Epidermal EGFR Controls Cutaneous Host Defense and Prevents Inflammation.
» Cutaneous Adverse Effects Associated With the Tyrosine-Kinase Inhibitor Cabozantinib.
» Va&&ine side effects
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum
|
|
Today at 11:16 am by CausticSymmetry
» zombie cells
Sat May 11, 2024 6:54 am by CausticSymmetry
» Sandalore - could it be a game changer?
Wed May 08, 2024 9:45 pm by MikeGore
» *The first scientific evidence in 2021 that viruses do not exist*
Tue May 07, 2024 4:18 am by CausticSymmetry
» China is at it again
Tue May 07, 2024 4:07 am by CausticSymmetry
» Ways to increase adult stem cells
Mon May 06, 2024 5:40 pm by el_llama
» pentadecanoic acid
Sun May 05, 2024 10:56 am by CausticSymmetry
» Exosome Theory and Herpes
Fri May 03, 2024 3:25 am by CausticSymmetry
» Road to recovery - my own log of everything I'm currently trying for HL
Tue Apr 30, 2024 1:55 pm by JtheDreamer